Program
CT-P55
Its studies are mostly in Psoriasis, led by Celltrion.
Furthest: phase 3, since Oct 7, 20242 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celltrion | 21 open or running | phase 3since Oct 7, 2024 | Oct 7, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2024First study: phase 3 study in Plaque PsoriasisFirst studyNCT06630559 · 153 enrolled · Poland
- Jun 22, 2025Phase 1 study in Healthy Male SubjectsNCT07054970 · 172 enrolled · Japan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07054970Healthy Male Subjects · Japan | 1 | Completed | Aug 29, 2024 | 172 |
| NCT06630559Plaque Psoriasis · Poland | 3 | Active, not recruiting | Feb 18, 2026 | 153 |
How it is read
Names in the registry
- “CT-P55”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.